Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials

Zoe D. Draelosa Dermatology Consulting Services, PLLC, High Point, NC, United StatesCorrespondence[email protected]

https://orcid.org/0000-0001-9803-7415 View further author information

Emil A. Tanghettib Center for Dermatology and Laser Surgery, Sacramento, CA, United StatesView further author information

Leon H. Kircikc Icahn School of Medicine at Mount Sinai, New York, NY, United States;d Indiana University Medical Center, Indianapolis, IN, United States;e Physicians Skin Care, PLLC, DermResearch, PLLC, and Skin Sciences, PLLC, Louisville, KY, United StatesView further author information

Neal Bhatiaf Therapeutics Clinical Research, San Diego, CA, United StatesView further author information

Joshua A. Zeichnerc Icahn School of Medicine at Mount Sinai, New York, NY, United StatesView further author information

Jeffrey L. Sugarmang University of California, San Francisco, CA, United StatesView further author information

Linda Stein Goldh Henry Ford Hospital, Detroit, MI, United StatesView further author information

show all

Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date